Calidi Biotherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Calidi Biotherapeutics han disminuido a una tasa media anual de -25.1%, mientras que en la industria Biotechs los beneficios crecieron en un 19.3% anualmente. Los ingresos han ido disminuyendo a una tasa media de 179.8% al año.

Información clave

-25.1%

Tasa de crecimiento de los beneficios

-7.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-179.8%
Rentabilidad financiera	n/a
Margen neto	n/a
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Calidi Biotherapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSEAM:CLDI Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	-28	17	11
30 Jun 24	-25	17	12
31 Mar 24	-30	17	13
31 Dec 23	-29	16	13
30 Sep 23	-29	17	11
30 Jun 23	-32	16	10
31 Mar 23	-24	15	8
31 Dec 22	-25	16	7
30 Sep 22	-21	11	6
31 Dec 21	-11	6	4

Ingresos de calidad: CLDI actualmente no es rentable.

Margen de beneficios creciente: CLDI actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CLDI no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 25.1% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CLDI en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CLDI no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: El pasivo de CLDI supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Calidi Biotherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado